MECOM and neoplasm: A high level of expression of EVI1 in this subtype—but not in the other KIRC subtypes (CC-e.1-2) and complete cohort—was found to be significantly associated with poorer outcome, as measured by a multivariate (including age, gender, and tumor stage) Cox regression analysis of progression-free interval (PFI; Figure 2B).